TABLE 2.
Demographic and clinical characteristics of the included subjects.
| Study | Subjects | Women | Age | Inpatients | Previous episodes | Duration of current episode (months) |
|---|---|---|---|---|---|---|
| Jahn et al. (2004) | Metyrapone (n = 33) | 54% | 45.2 ± 13.8 | 100% | 2 | 3 |
| Placebo (n = 30) | 53% | 46.5 ± 13.0 | 100% | 2 | 3.5 | |
| McAllister-Williams et al. (2016) | Metyrapone (n = 83) | 57% | 47.6 ± 9.9 | 100% | — | — |
| Placebo (n = 82) | 63% | 45.2 ± 10.4 | 100% | — | — | |
| O’Dwyer et al. (1995) | Metyrapone (n = 4) | 75% | 40.3 ± 8.4 | 100% | — | — |
| Placebo (n = 4) | 100% | 39.5 ± 7.5 | 100% | — | — | |
| Rogoz et al. (2004) | N = 9 | 67% | 52.4 ± 2.3 | 100% | 6.4 ± 0.7 | — |
| Block et al. (2018) | Mifepristone (n = 833) | 58% | 44.7 ± 11.6 | Most were outpatients | — | — |
| (300 mg n = 110, 600 mg n = 471, 1200 mg n = 252) | 60% | 44.7 ± 11.2 | — | — | ||
| Women, age, ect. | Placebo (n = 627) | |||||
| Watson et al. (2012) | Mifepristone (n = 30) | 50% | 48 ± 9.3 | 0 | — | 17 ± 20 |
| Placebo (n = 30) | 43% | 48 ± 9.5 | 0 | — | 12 ± 18.8 | |
| Belanoff et al. (2001) | Mifepristone (n = 2) | 0% | 47.5 ± 3.5 | 100% | 0 | 5.5 ± 3.5 |
| Placebo (n = 3) | 67% | 56 ± 11.5 | 100% | 1 | 7.0 ± 9.5 | |
| Flores et al. (2006) | Mifepristone (n = 15) | 60% | 36.4 ± 13.2 | — | — | — |
| Placebo (n = 15) | 53% | 38.8 ± 12.9 | — | — | - | |
| DeBattista et al. (2006) | Mifepristone (n = 105) | 47% | 40.9 ± 10.8 | — | — | — |
| Placebo (n = 116) | 52% | 41.6 ± 11.0 | — | — | — | |
| Belanoff et al. (2002) | 50 mg mifepristone (n = 11) | 55% | 42.3 ± 11.6 | 100% | — | 3.7 ± 4.2 |
| 600 mg + 1200 mg mifepristone (n = 19) | 68% | 47.0 ± 14.8 | 100% | — | 4.3 ± 6.5 | |
| Simpson et al. (2005) | Mifepristone (n = 20) | 30% | 46.0 ± 10.8a | 100% | — | — |
| Wolkowitz et al. (1999) | Ketoconazole (n = 9) | 60% (total) | 46.9 ± 14.0 (total) | 0% | — | — |
| Placebo (n = 11) | 0% | — | — | |||
| Malison et al. (1999) | Ketoconazole (n = 8) | 50% | 44 ± 8 | 75% | — | — |
| Placebo (n = 8) | 25% | 45 ± 14 | 62.5% | — | — | |
| Thakore et al. (1994) | Ketoconazole (n = 8) | 50% | 42.7 ± 2.3 | 100% | — | — |
| Paslakis et al. (2011) | Ketoconazole (n = 6) | 33% | 66.8 ± 11.1 | 100% | 1.5 ± 1.5 | 31.2 ± 22.0 |
| Kamiya et al. (2020) | TS-121 10 mg (n = 14) | 62.5% | 44.8 ± 12.6 | — | — | 10.9 ± 15.1 |
| TS-121 50 mg (n = 15) | 68.8% | 44.8 ± 12.9 | — | — | 17.9 ± 25.6 | |
| Placebo (n = 17) | 66.7% | 45.8 ± 11.1 | — | — | 24.9 ± 54.3 | |
| Griebel et al. (2012) | 67.5% | 41.0 ± 10.7 | 0% | — | — | |
| SSR 200 mg (n = 77) | 50.6% | 42.0 ± 11.0 | 0% | — | — | |
| SSR 500 mg (n = 70) | 63.2% | 41.2 ± 12.4 | — | — | ||
| Placebo (n = 71) | 74.7% | 43.0 ± 12.4 | — | — | ||
| 70.7% | 41.6 ± 11.9 | — | — | |||
| SSR 200 mg (n = 79) | 73.4% | 40.1 ± 10.6 | — | — | ||
| SSR 500 mg (n = 78) | ||||||
| Women, age, ect. | Placebo (n = 76) | |||||
| Katz et al. (2017) | ABT-436 (n = 31) | 35% (total) | 35.5 ± 9.95 (total) | — | — | 27.6 ± 50 |
| Placebo (n = 20) | 14.9 ± 25 | |||||
| Binneman et al. (2008) | CP-316,311 (n = 28) | 39% | 50 ± 13.5 | 0% | — | — |
| Placebo (n = 31) | 35% | 49 ± 11 | 0% | — | — | |
| NCT00733980 | GSK561679 (n = 74) | 100% | 38.8 ± 11.3 | — | — | — |
| Placebo (n = 76) | 100% | 40.8 ± 12.2 | — | — | — | |
| Zobel et al. (2000) | R121919 (n = 20) | 45% | 47.2 ± 12.2 | — | — | 4.5 ± 2.7 |
| Dinan et al. (1997) | Dexamethasone (n = 10) | 60% | 35.4 ± 7.9 | — | 1.1 ± 1.3 | 4.0 ± 1.5 |
| Otte et al. (2010) | Fludrocortisone (n = 24) | 63% | 36.5 ± 12.7 | 67% | 1.5 ± 1.4 | 7.4 ± 5.4 |
| Spironolactone (n = 27) | 61% | 36.7 ± 10.6 | 63% | 0.6 ± 0.9 | 8.0 ± 9.9 | |
| Placebo (n = 13) | 64% | 34.5 ± 12.7 | 75% | 0.8 ± 1.2 | 5.2 ± 3.3 |